Rafferty Asset Management
NRIX icon

Rafferty Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Rafferty Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.32M Buy
149,523
+59,008
+65% +$978K 0.01% 575
2025
Q4 		$1.72M Sell
90,515
-1,930
-2% -$27.7K 0.01% 684
2025
Q3 		$854K Buy
92,445
+16,722
+22% +$174K ﹤0.01% 826
2025
Q2 		$862K Sell
75,723
-34,359
-31% -$371K ﹤0.01% 787
2025
Q1 		$1.31M Sell
110,082
-6,104
-5% -$102K 0.01% 681
2024
Q4 		$2.19M Buy
116,186
+22,593
+24% +$518K 0.01% 628
2024
Q3 		$2.1M Sell
93,593
-43,723
-32% -$990K 0.01% 623
2024
Q2 		$2.87M Sell
137,316
-74,109
-35% -$1.15M 0.01% 542
2024
Q1 		$3.11M Buy
+211,425
New +$2.27M 0.01% 575
2023
Q4 		– Sell
-98,839
Closed -$777K – 1090
2023
Q3 		$777K Sell
98,839
-15,649
-14% -$143K ﹤0.01% 853
2023
Q2 		$1.14M Sell
114,488
-25,659
-18% -$262K 0.01% 788
2023
Q1 		$1.24M Sell
140,147
-24,932
-15% -$260K 0.01% 743
2022
Q4 		$1.81M Buy
165,079
+34,170
+26% +$412K 0.02% 607
2022
Q3 		$1.71M Buy
130,909
+59,860
+84% +$947K 0.02% 546
2022
Q2 		$900K Sell
71,049
-75,231
-51% -$853K 0.01% 683
2022
Q1 		$2.05M Buy
146,280
+55,574
+61% +$986K 0.01% 594
2021
Q4 		$2.63M Buy
90,706
+31,840
+54% +$965K 0.01% 573
2021
Q3 		$1.76M Sell
58,866
-19,824
-25% -$612K 0.01% 676
2021
Q2 		$2.09M Buy
78,690
+10,863
+16% +$319K 0.01% 675
2021
Q1 		$2.11M Buy
+67,827
New +$2.57M 0.01% 606

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Rafferty Asset Management's NRIX Position: Q1 2026 in Review

Rafferty Asset Management increased its Nurix Therapeutics (NRIX) stake by 65% in Q1 2026, buying an estimated $978K and bringing the position to 149,523 shares worth $2.32M. The position accounts for 0.01% of the portfolio, ranked #575.

Rafferty Asset Management first reported a position in NRIX in Q1 2021 and has held it in 20 quarters since. The position peaked at $3.11M in Q1 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Rafferty Asset Management held 149,523 shares of Nurix Therapeutics worth $2.32M as of Q1 2026.
  • Rafferty Asset Management bought 59,008 Nurix Therapeutics shares in Q1 2026, an estimated $978K.
  • Nurix Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #575 holding.
  • Rafferty Asset Management first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Rafferty Asset Management's Nurix Therapeutics position peaked at $3.11M in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.